



Trendlines May 2016 Update

Misgav, Israel – 1 June 2016 – The Trendlines Group Ltd. ("Trendlines") is pleased to provide this update about its recent activities and developments related to its portfolio companies.

Trendlines' Announced Q1 2016 Unaudited Financial Results

On 10 May 2016, Trendlines published its unaudited financial results for Q1 2016 [which can be read here](#).

Trendlines Launches ADR Program

Trendlines [announced the launch of a sponsored Level 1 American Depositary Receipt \(ADR\) program on 16 May 2016](#). The ADR program will support the expansion of the Company's investor base in the United States of America ("U.S.") and the ADRs are traded in the Over the Counter (OTC) market. The ticker symbol for the Trendlines ADR on the OTC is "TRNLY." Each Trendlines ADR represents 50 ordinary shares of the Company (SGX:42T) trading on the Catalist of the Singapore Exchange Securities Trading Limited.

Trendlines Welcomes Judith Kleinman as Director, Investor Relations & Corporate Communications

Judy brings 15 years' investor relations experience for tech companies in the United Kingdom and Israel, and 10 years' experience in equity research and institutional equity sales. Her e-mail is judith@trendlines.com.

Trendlines Participated at International Annual Biomed Conference

For the 11th consecutive year, [Trendlines exhibited at Biomed](#), the annual life sciences conference in Israel. CEOs of Trendlines Medical's portfolio companies and Trendlines' staff were on hand to answer questions about products and technologies.

Updated Investor Presentation

We updated our [investor presentation which can be found on our website](#).

New Agtech Company Established

Trendlines Agtech established a new company: InPlant Technologies develops delivery technologies to increase the mobility of agrochemical actives in the plant, enhancing their activity or reducing the required dosage, resulting in higher yields and lower environmental impact.

News from Trendlines' Portfolio Companies

BioSight Ltd. [raised US\\$13 million](#) to fund a multi-center trial for Astarabine, its drug for use in the treatment of acute myeloid leukemia (AML).

Arcuro Medical Ltd. is developing a novel meniscus (knee cartilage) repair system. The company announced its [completion of a US\\$670,000 financing round](#) led by China's Naton Medical Group and U.S. angel investors.

Gordian Surgical Ltd. recently began [first-in-human \(FIH\) trials](#) with its TroClose1200™, an innovative trocar with an integrated closure mechanism for the safe, easy, and effective suturing of incisions in the abdominal wall during laparoscopic surgery.

LapSpace Medical Ltd. received a U.S. patent for its inflatable retractor. CEO **Assaf Livne** says the patent gives “very strong coverage of the LapSpace technology.”

Virentes Ltd. reports [success from its test sites](#) in Israel’s Arava region.

Upcoming Events

First Trendlines Medical Asia Road Show

From 4-8 July 2016, Trendlines Medical will bring 7 portfolio companies to Asia on [a medical technology road show](#). These companies are ElastiMed Ltd., Escala Medical Ltd., Fidmi Medical Ltd., Gordian Surgical Ltd., Leviticus Cardio Ltd., OrthSpin Ltd., and ProArc Medical Ltd. The companies will present in **Singapore, Hong Kong, Shenzhen, Shanghai, and Beijing**.

For information, contact Andi Chai (andi@trendlines.com), Reyna Mei (reyna@financialpr.com.sg), or Eddy Wang (eddy@trendlines.com).

The Trendletter, our monthly newsletter provides information and news articles about our organization, companies and events. [Read the latest Trendletter here](#).

To sign up for The Trendletter, [subscribe here](#).

To sign up for SGXNet updates, please register at <http://investors.trendlines.com/siteservices/e-mail-alerts>.

- End -

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist.

The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.